The plasma pharmacokinetics of adriamycin after intrapleural administration have been studied. The maximum plasma concentration found after intrapleural instillation of 50 mg was 100 ng ml−1, the adriamycin half-life being about 2.5 h.
Large amounts of the drug are adsorbed from the pleura. Hence risks for cardiomyopathy, previously associated with the repeated intravenous administration of adriamycin, must also be considered after intrapleural administration.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Blum R H, Carter S K: Adriamycin, a new anticancer drug with significant clinical activity.Ann intern Med 80, 249–259, (1974).
Carter S K: Adriamycin—a review.J natn Cancer Inst 55, 1265–1274 (1975).
Minow R A, Benjamin R S, Lee E T, Gottlieb J A: Adriamycin cardiomyopathy—risk factors.Cancer 39, 1397–1402 (1977).
Lenaz L, Page J A: Cardiotoxicity of adriamycin and related anthracyclines.Cancer Treat Rev 3, 111–120 (1976).
Banks M D, Pontes J E, Izbicki R M, Pierce J M Jr: Topical instillation of doxorubicin hydrochloride in treatment of recurring superficial transitional cell carcinoma of the bladder.J Urol 118, 757–760 (1977).
Ozaki Y: Bladder instillation of adriamycin in the treatment of bladder tumours. Report 1: Clinical results.Jap J Urol 68, 934–944 (1977).
Eksborg S, Nilsson S O, Edsmyr F: Intravesical instillation of adriamycin—a model for standardization of the chemotherapy.Eur J Urol 6, 218–220 (1980).
Eksborg S: Measurements of plasma levels of adriamycin and adriamycinol after intravesical instillation of adriamycin, in:Diagnostics and Treatment ofSuperficial Urinary Bladder Tumours, pp. 55–58. Stockholm Montedison Läkemdel AB, (1979).
Jacobi G H, Kurth K H: Studies on the intravesical action of topically administered G3H-doxorubicin hydrochloride in men: plasma uptake and tumour penetration.J Urol 124, 34–37 (1980).
Tattersall M H N, Fox R M, Newlands E S, Woods R L: Intracavitary doxorubicin in malignant effusions.Lancet 8112, 390 (1979).
Desai S D, Figueredo A: Intracavitary doxorubicin in malignant effusions.Lancet 8121, 872 (1979).
Kefford R F, Woods R L, Fox R M, Tattersall M H N: Intracavitary adriamycin, nitrogen mustard and tetracycline in the control of malignant effusions.Med J Aust 2, 447–448 (1980).
Eksborg S, Ehrsson H, Andersson I: Reversed-phase liquid chromatographic determination of plasma levels of adriamycin and adriamycinol.J Chromatog 164, 479–486 (1979).
Benjamin R S: Pharmacokinetics of adriamycin in (NSC-123127) in patients with sarcomas.Cancer Chemother Rep 58, Part 1, 271–273 (1974).
Bachur N R: Adriamycin (NSC-123127) pharmacology.Cancer Treat Rep 6, Part 3, 153–158 (1975).
Praga C, Beretta P L, Vigo G Ret al.: Adriamycin cardiotoxicity: a survey of 1237 patients.Cancer Treat Rep 63, 827–834 (1979).
About this article
Cite this article
Eksborg, S., Lindfors, A. & Cedermark, B.J. Plasma pharmacokinetics of adriamycin after intrapleural administration. Med. Oncol. & Tumor Pharmacother. 1, 193–194 (1984). https://doi.org/10.1007/BF02934140
- Pleural effusions